Biotech | September 18, 2021
Excision receives U.S. FDA clearance for first-in-human CRISPR Phase I/II trail for HIV
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Initially launched in Europe, this new service gives customers access to a range of digital health services and medical professionals and is part of its Digital Access to Care Initiative
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
Proceeds raised from the duathlon will go towards cancer treatment of children identified by the hospital
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
Crosscope and KFBIO join forces to lead digital transformation for pathology in India and emerging markets
The tracker gives week by week coverage of the first and second dose of vaccine and also their effectiveness
Subscribe To Our Newsletter & Stay Updated
